التفاصيل البيبلوغرافية
| العنوان: |
Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma*. |
| المؤلفون: |
Mulder, E.E.A.P., Dwarkasing, J.T., Tempel, D., Spek, A., Bosman, L., Verver, D., Mooyaart, A.L., Veldt, A.A.M., Verhoef, C., Nijsten, T.E.C., Grunhagen, D.J., Hollestein, L.M. |
| المصدر: |
British Journal of Dermatology; May2021, Vol. 184 Issue 5, p944-951, 8p |
| مصطلحات موضوعية: |
SENTINEL lymph nodes, GENE expression profiling, LYMPHATIC metastasis, ISOLATION perfusion, SENTINEL lymph node biopsy |
| مستخلص: |
Summary: Background: The Clinicopathological and Gene Expression Profile (CP‐GEP) model was developed to accurately identify patients with T1–T3 primary cutaneous melanoma at low risk for nodal metastasis. Objectives: To validate the CP‐GEP model in an independent Dutch cohort of patients with melanoma. Methods: Patients (aged ≥ 18 years) with primary cutaneous melanoma who underwent sentinel lymph node biopsy (SLNB) between 2007 and 2017 at the Erasmus Medical Centre Cancer Institute were eligible. The CP‐GEP model combines clinicopathological features (age and Breslow thickness) with the expression of eight target genes involved in melanoma metastasis (ITGB3, PLAT, SERPINE2, GDF15, TGFBR1, LOXL4, CXCL8 and MLANA). Using the pathology result of SLNB as the gold standard, performance measures of the CP‐GEP model were calculated, resulting in CP‐GEP high risk or low risk for nodal metastasis. Results: In total, 210 patients were included in the study. Most patients presented with T2 (n = 94, 45%) or T3 (n = 70, 33%) melanoma. Of all patients, 27% (n = 56) had a positive SLNB, with nodal metastasis in 0%, 30%, 54% and 16% of patients with T1, T2, T3 and T4 melanoma, respectively. Overall, the CP‐GEP model had a negative predictive value (NPV) of 90·5% [95% confidence interval (CI) 77·9–96.2], with an NPV of 100% (95% CI 72·2–100) in T1, 89·3% (95% CI 72·8–96·3) in T2 and 75·0% (95% CI 30·1–95·4) in T3 melanomas. The CP‐GEP indicated high risk in all T4 melanomas. Conclusions: The CP‐GEP model is a noninvasive and validated tool that accurately identified patients with primary cutaneous melanoma at low risk for nodal metastasis. In this validation cohort, the CP‐GEP model has shown the potential to reduce SLNB procedures in patients with melanoma. What is already known about this topic?The majority (70–85%) of patients with cutaneous melanoma who undergo a sentinel lymph node biopsy (SLNB) procedure have no metastasis in the SLN.To identify patients at low risk for nodal metastasis, the Clinicopathological and Gene Expression Profile (CP‐GEP) model was developed (n = 754 patients, US cohort).The CP‐GEP model combines age, Breslow thickness and the expression of eight target genes involved in melanoma metastasis, and has the potential to reduce SLNB procedures in patients with T1–T3 cutaneous melanoma. What does this study add?This is the first independent validation of the CP‐GEP model in European patients with primary cutaneous melanoma.The CP‐GEP model can be applied to full‐excision tumour tissue and does not require macrodissection of tumour tissue.The CP‐GEP model has a negative predictive value of 90·5% (95% confidence interval 77·9–96·2) in T1–T3 melanomas.The CP‐GEP model is a promising tool in patient care. In this validation cohort, the CP‐GEP model has shown the potential to reduce SLNB procedures in patients with primary cutaneous melanoma. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder